Please login to the form below

Not currently logged in
Email:
Password:

NOR-SWITCH

This page shows the latest NOR-SWITCH news and features for those working in and with pharma, biotech and healthcare.

Standing out in a crowd

Standing out in a crowd

explained. Switching. Once products reached the market Celltrion observed further challenges when it came to persuading physicians to switch patients from originator biologics to their biosimilar equivalents. ... This is despite work to study the effects

Latest news

  • Facing the new wave of biosimilars Facing the new wave of biosimilars

    One trial, the NOR-SWITCH study, has made a significant contribution to the evidence base for switching. ... Some policy makers have interpreted NOR-SWITCH results as confirmation of switching’s safety and efficacy.

  • Pfizer’s Remicade biosimilar receives Crohn's trial boost Pfizer’s Remicade biosimilar receives Crohn's trial boost

    In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across ... That issue has already been studied to some extent in the NOR-SWITCH

  • NOR-SWITCH - the final piece in the biosimilar puzzle? NOR-SWITCH - the final piece in the biosimilar puzzle?

    that policymakers do not misinterpret or exaggerate the findings of the NOR-SWITCH trial. ... NOR-SWITCH is designed to evaluate the effects of a switch from the original biologic to a biosimilar.

  • Study finds no problems switching from Remicade to biosimilar Study finds no problems switching from Remicade to biosimilar

    The comparative trial - called NOR-SWITCH - was presented at the 2016 UEG Week in Vienna, Austria and showed that swapping from Remicade to a biosimilar version made by Celltrion posed no ... The data shows that safety and efficacy are maintained

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....